Sri Lanka has taken a landmark step in its healthcare journey by commencing local production of Fluorodeoxyglucose (FDG), a vital radiopharmaceutical used in Positron Emission Tomography-Computed Tomography (PET-CT) scans. This development marks a significant milestone in the country's efforts to strengthen its cancer diagnosis capabilities, reduce dependency on costly imports, and make advanced medical imaging more accessible to patients across the island nation.
What Is FDG and Why Does It Matter?
Fluorodeoxyglucose, commonly known as FDG, is a radioactive glucose compound that plays a central role in PET-CT scanning — one of the most powerful diagnostic tools available in modern oncology. When injected into a patient's body, FDG is absorbed by metabolically active cells, including cancer cells, which consume glucose at a much higher rate than normal tissue. The PET-CT scanner then detects the radiation emitted by the compound, producing detailed images that allow doctors to identify tumors, assess cancer spread, and monitor the effectiveness of treatment.
PET-CT scans are widely regarded as superior to conventional imaging methods for detecting many types of cancer at early stages. However, because FDG is radioactive and has an extremely short half-life of approximately 110 minutes, it must be produced close to where it will be used. This logistical challenge has historically made PET-CT scanning expensive and difficult to access in countries that lack local production facilities.
A Game-Changer for Sri Lanka's Cancer Care
Prior to this development, Sri Lanka relied entirely on imported FDG, which significantly limited the availability of PET-CT scans for patients. The short shelf life of the drug meant that importing it from overseas was not a practical long-term solution, resulting in restricted access to this critical diagnostic tool. Patients requiring PET-CT scans often faced long waiting times, high costs, or the difficult prospect of travelling abroad to receive the imaging they needed.
With local production now underway, Sri Lanka is poised to dramatically expand access to PET-CT scanning services. Hospitals and cancer treatment centers across the country will be able to receive freshly produced FDG on a regular basis, enabling more patients to benefit from accurate and timely cancer diagnoses. This is expected to have a direct and positive impact on patient outcomes, as early detection remains one of the most critical factors in successful cancer treatment.
Reducing the Burden of Cancer in Sri Lanka
Cancer is one of the leading causes of death in Sri Lanka, with thousands of new cases diagnosed each year. The disease places an enormous burden on the country's healthcare system, on families, and on the national economy. Delayed diagnosis, which is often linked to limited access to advanced imaging technologies, can allow cancers to progress to later stages where treatment becomes more complex, less effective, and significantly more expensive.
By enabling earlier and more accurate detection of cancer through improved access to PET-CT scans, local FDG production has the potential to save lives and reduce the overall cost of cancer care in Sri Lanka. Oncologists and healthcare professionals have long advocated for greater investment in diagnostic infrastructure, and this initiative represents a meaningful response to those calls.
Strengthening Local Pharmaceutical Capabilities
The commencement of FDG production is also a reflection of Sri Lanka's growing ambitions in the field of pharmaceutical manufacturing. Producing a radiopharmaceutical of this complexity requires sophisticated equipment, highly trained personnel, and strict adherence to international safety and quality standards. The successful establishment of local FDG production demonstrates that Sri Lanka has the technical capacity and institutional commitment to advance its pharmaceutical sector beyond conventional medicines.
This achievement could also open doors for the country to explore the local production of other radiopharmaceuticals and advanced medical compounds in the future, further reducing import dependency and strengthening healthcare self-sufficiency. In the context of global supply chain vulnerabilities that were exposed during the COVID-19 pandemic, building domestic production capacity for critical medical inputs is a strategically sound investment.
A Step Toward Universal Health Access
At its core, the local production of FDG is about equity in healthcare. Advanced cancer diagnostics should not be a privilege reserved for those who can afford to travel abroad or pay premium prices for imported services. By bringing this capability within Sri Lanka's borders, the government and relevant health authorities are taking a concrete step toward ensuring that more citizens — regardless of their economic status or geographic location — can access the diagnostic tools they need.
As Sri Lanka continues to build and modernize its healthcare infrastructure, the successful launch of domestic FDG production stands as a beacon of progress. It signals a future where cutting-edge medical technology is not out of reach, and where the fight against cancer is supported by robust, locally grounded scientific capability. This is not just a pharmaceutical achievement — it is a public health victory for the people of Sri Lanka.